BioCryst Pharmaceuticals, Inc.

Contributing Author

Recent Articles by BioCryst Pharmaceuticals, Inc.

Dec-12	BioCryst Announces FDA Approval of ORLADEYO (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years BCRX GlobeNewswire
Dec-04	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Dec-03	BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition BCRX GlobeNewswire
Nov-06	BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO (berotralstat) BCRX GlobeNewswire
Nov-05	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Nov-05	BioCryst to Present at Upcoming Investor Conference BCRX GlobeNewswire
Nov-03	BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
Oct-23	BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting BCRX GlobeNewswire
Oct-20	BioCryst to Report Third Quarter 2025 Financial Results on November 3 BCRX GlobeNewswire
Oct-14	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile BCRX GlobeNewswire
Oct-03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Oct-01	BioCryst Completes Sale of European ORLADEYO (berotralstat) Business BCRX GlobeNewswire
Sep-03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Aug-21	BioCryst to Present at Upcoming Investor Conference BCRX GlobeNewswire
Aug-11	BioCryst Announces Departure of Dr. Helen Thackray BCRX GlobeNewswire
Aug-06	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Aug-04	BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
Jul-31	BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December BCRX GlobeNewswire
Jul-21	BioCryst to Report Second Quarter 2025 Financial Results on August 4 BCRX GlobeNewswire
Jul-09	BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit BCRX GlobeNewswire
Jul-07	BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development BCRX GlobeNewswire
Jul-03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Jun-27	BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million BCRX GlobeNewswire
Jun-16	BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO (berotralstat) Across all Ages at EAACI BCRX GlobeNewswire
Jun-13	ORLADEYO (berotralstat) Approved in Colombia BCRX GlobeNewswire
Jun-06	BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries BCRX GlobeNewswire
Jun-03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Jun-02	BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology BCRX GlobeNewswire
May-30	BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages BCRX GlobeNewswire
May-27	BioCryst to Present at Upcoming Investor Conferences BCRX GlobeNewswire
May-16	BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) BCRX GlobeNewswire
May-14	BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years BCRX GlobeNewswire
May-05	BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
May-02	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire

BioCryst Pharmaceuticals, Inc.

Recent Articles by BioCryst Pharmaceuticals, Inc.

Upgrade your FINVIZ experience